Astellas Pharma US | Changing Tomorrow | Home

Previous Pause Next

Astellas Celebrates Decade of Service by Volunteering 80,000 Hours to Help Local Communities

Astellas Celebrates Decade of Service by Volunteering 80,000 Hours to Help Local Communities Read More

Astellas ranks in Top 10 of Working Mother Best Companies list

Astellas Ranks in Top 10 of Working Mother Best Companies list Read More

Learn How Astellas is Changing Cancer Care with the C3Prize

Learn How Astellas is Changing Cancer Care with the C3Prize Read More

1

2

3

News

Latest

News / Media

Sep 02, 2019

RIKEN and Astellas Enter into Worldwide Exclusive Licensing Agreement for Artificial Adjuvant Vector Cell Technology in Oncology

News / Media

Aug 09, 2019

Yokohama City University, Tokyo University of the Arts and Astellas Launched Health Mock Lab. to Create New Digital Healthcare Solutions Using Gamification

News / Media

Aug 06, 2019

Astellas Initiates Phase 3 Clinical Trials for Fezolinetant in Postmenopausal Women with Vasomotor Symptoms

News / Corporate

Oct 31, 2019

New England Journal of Medicine Publishes Results from Astellas' Phase 3 ADMIRAL Trial of XOSPATA® (gilteritinib) in Adult Patients with FLT3 Mutation-Positive Relapsed/Refractory Acute Myeloid Leukemia(1)

News / Therapeutic Area News

Oct 28, 2019

U.S. FDA Grants Fast Track Designation to Astellas for the Development of ASP1128 for Patients at Risk for Acute Kidney Injury

News / Corporate

Oct 28, 2019

Astellas Oncology Announces Grand Prize Winner of 2019 C3 Prize® to Improve Cancer Care